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Abstract
Purpose: To report our experience with intensity-modulated or stereotactic reirradiation in patients suffering from
recurrent nasopharyngeal carcinoma.
Patients and Methods: The records of 17 patients with recurrent nasopharygeal carcinoma treated by intensity-
modulated (n = 14) or stereotactic (n = 3) reirradiation in our institution were reviewed. Median age was 53 years
and most patients (n = 14) were male. The majority of tumors showed undifferentiated histology (n = 14) and
infiltration of intracranial structures (n = 12). Simultaneous systemic therapy was applied in 8 patients. Initial
treatment covered the gross tumor volume with a median dose of 66 Gy (50-72 Gy) and the cervical nodal regions
with a median dose of 56 Gy (50-60 Gy). Reirradiation was confined to the local relapse region with a median dose
of 50.4 Gy (36-64Gy), resulting in a median cumulative dose of 112 Gy (91-134 Gy). The median time interval
between initial and subsequent treatment was 52 months (6-132).
Results: The median follow up for the entire cohort was 20 months and 31 months for survivors (10-84). Five
patients (29%) developed isolated local recurrences and three patients (18%) suffered from isolated nodal
recurrences. The actuarial 1- and 2-year rates of local/locoregional control were 76%/59% and 69%/52%,
respectively. Six patients developed distant metastasis during the follow up period. The median actuarial overall
survival for the entire cohort was 23 months, transferring into 1-, 2-, and 3-year overall survival rates of 82%, 44%
and 37%. Univariate subset analyses showed significantly increased overall survival and local control for patients
with less advanced rT stage, retreatment doses > 50 Gy, concurrent systemic treatment and complete response.
Severe late toxicity (Grad III) attributable to reirradiation occurred in five patients (29%), particularly as hearing loss,
alterations of taste/smell, cranial neuropathy, trismus and xerostomia.
Conclusion: Reirradiation with intensity-modulated or stereotactic techniques in recurrent nasopharyngeal
carcinoma is feasible and yields encouraging results in terms of local control and overall survival in patients with
acceptable toxicity in patients with less advanced recurrences. However, the achievable outcome is limited in
patients with involvement of intracranial structures, emphasising the need for close monitoring after primary
therapy.
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Radiotherapy with or without simultaneous chemother-
apy according to stage is the standard of care for pri-
mary nasopharyngeal cancer resulting in excellent local
control and overall survival rates [1-6]. However, local
or locoregional failure still represents a major failure
pattern, especially in advanced T stage [7]. Although
several treatment options for local relapses exist, includ-
ing surgery, chemotherapy and reirradiation with various
techniques, treatment remains challenging due to close
organs at risk with high impact on functional outcome.
While surgery is the preferable treatment option for
regional lymph node failure in patients treated primarily
with combined chemoradiation [8], its use in local
recurrences of the nasopharynx itself often needs
demanding procedures. Surgery is especially challenging
in locally advanced lesions because of the difficult expo-
sure of this region, and flawed with a high risk of func-
tional deficits. Chemotherapy alone is the treatment of
choice in patients with metastastic disease, but has to be
considered as a palliative treatment option only for
patients with localized recurrence not amendable to
local treatment options, at least as long term survivors
have rarely been described [9]. Because nasopharyngeal
cancer is known to be sensitive to radiation therapy,
reirradiation has been used in various approaches to
treat local recurrences [7]. Brachtherapy techniques
have been described either as intracavitary mould tech-
niques for recurrent lesions confined to the nasopharynx
[10] or by the use of interstitial gold grain implants for
more advanced lesions, resulting in good local control
and overall survival rates [11], but are restricted to a
small number of highly specialized and experienced cen-
ters. Stereotactic single dose radiotherapy, also known
as radiosurgery, has also been described as a valid treat-
ment option for small recurrent lesions [12] but could
result in significant toxicity due to the unfavourable
radiobiology of single dose treatments if used for
advanced lesions. Because fractionated external beam
radiotherapy should offer a more favourable radiobiol-
ogy in terms of toxicity, it has been used for almost two
decades for the treatment of recurrent nasopharyngeal
cancer. Although achieving acceptable results in terms
of local control, a significant number of late sequelae
has been reported especially in the early literature using
3-dimensional (3D) or even 2-dimensional (2D) radia-
tion treatment techniques due to the lack of conformal-
ity with adaequate sparing of adjacent organs at risk
[13-15]. However, radiation therapy techniques have
emerged consistently over time, and the introduction of
fractionated stereotactic or intensity-modulated radio-
therapy should theoretically result in a more favourable
balance between target coverage and sparing of adjacent
organs at risk especially in complex shaped advanced
recurrent nasopharyngeal lesions [16]. To confirm this
assumption in daily clinical routine, we report our
experience using intensity-modulated radiotherapy in
the treatment of previously irradiated localized recur-
rences of nasopharyngeal cancer.
Patients and Methods
A total of 17 patients with recurrent nasopharyngeal
cancer have been treated in our institution with fractio-
nated intensity modulated or stereotactic reirradiation.
All patients suffered from histologically proven localized
recurrent nasopharyngeal cancer without distant metas-
tasis. Initial work-up included clinical examination, CT
and/or MRI of the head and neck region, panendoscopy
with histological confirmation, chest x ray or CT of the
lung, abdominal ultrasound or CT and bone scan for
the exclusion of distant metastases, laboratory examina-
tions and review of the former radiotherapy reports.
Median age at reirradiation was 53 years (range 23-
67 years) and most patients (n = 14) were male. The
majority of tumors showed undifferentiated histology
(Grade III according to WHO classification, n = 14) and
infiltration of cranial structures (rT4, n = 12). For
detailed patient characteristics see table 1. Initial radia-
tion treatment covered the primary tumor with a med-
ian dose of 66 Gy (50-72 Gy) and except in one patient,
the bilateral cervical and supraclavicular nodal regions
w i t ham e d i a nd o s eo f5 6G y( 5 0 - 6 0G y ) .T h em e d i a n
time interval between the initial and present treatment
was 52 months (6-132 months). Reirradiation was per-
formed using step-and-shoot intensity modulated radio-
therapy (IMRT) in 14 patients and fractionated
stereotactic radiotherapy (FSRT) in 3 patients. The tech-
niques of IMRT and FSRT used in our institution have
been previously described [17-23]. Briefly, all patients
were fixed in an individually manufactured precision
head mask made of Scotch cast
® (3 M, St.Paul, Minnea-
polis, MN). With this immobilization system attached to
the stereotactic base frame, contrast-enhanced CT- and
MRI-images were performed with a slice thickness of
3 mm. After stereotactic image fusion based on the
localizer-derived coordinate system, all critical structures
as well as the target volumes were defined on each slice
of the three-dimensional data cube. The gross tumor
volume (GTV) was defined as the macroscopic tumor
visible on CT- and MRI-scans. A margin of 5 mm was
a d d e df o rt h ec l i n i c a lt a r g e tv o l u m e( C T V )a n dt h e
planning target volume (PTV) was generated by adding
5 mm margin to the CTV. Margins could have been
reduced in regions of directly adjacent radiosensitive
organs at risk. Only two patients showed involved
lymph nodes in recurrent situation. In one patient the
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tion and therefore not included into the reirradiation
volume, in the second patient the lymph nodes were
included into the reirradiation volume and treated with
the same dose as the local recurrence. No elective reir-
radiation of uninvolved regional lymph nodes was per-
formed. Inverse treatment-planning was performed
using the KonRad software developed at the German
Cancer Research Center (DKFZ), which is connected to
the 3D planning program VIRTUOS to calculate and
visualize the 3D dose distribution. The IMRT treatment
planning process has also been described in detail pre-
viously [17,20-23]. Reirradiation treatment was delivered
by a Siemens accelerator (Primus, Siemens, Erlangen,
Germany) with 6 or 15 MV photons using an integrated
motorized multileaf collimator (MLC) for the step-and-
shoot technique automatically delivering the sequences.
T h et o t a ld o s e sw e r ep r e s c r i b e dt ot h em e d i a no ft h e
PTV and usually the 95% isodose surrounded the PTV.
An example of a three dimensional dose distribution is
shown in figure 1. The prescribed dose ranged from 36
to 64 Gy with a median dose of 50.4 Gy in conventional
fractionation (single dose 1.8-2 Gy, 5 fractions per
week), resulting in a median cumulative dose of 112 Gy
(range 91 - 134 Gy). Simultaneous systemic therapy was
applied in 8 patients (platin-based chemotherapy in
7 patients, cetuximab in one patient). For detailed treat-
ment characteristics see table 2. Doses to critical organs
at risk were kept as low as possible. Assuming a 50%
dose tolerance recovery of CNS structures from the
initial treatment course, no patient received more than
60 Gy to the brainstem and 50 Gy to the spinal cord.
For detailed information regarding the distribution of
dose to organs at risk see table 3. Regular follow-up
examinations took place in our institution or in the
referring centers including at least clinical examination
and CT or MRI of the head and neck region. Acute
toxicity was scored according to CTCAE V3.0, late toxi-
city was scored according to RTOG criteria. In case of
missing follow-up examinations, data was completed by
calling the patient or the treating physician. Time to
event data was calculated from the first day of radiation
treatment until the last follow up information or until
death. Response to treatment was based on CT or MRI
findings 6 weeks to 3 months after the end of treatment
according to RECIST criteria. Local control was defined
as absence of tumor regrowth in the region of the trea-
ted recurrence on repeated CT or MRI scans based on
best response after treatment. For example, if a patient
had stable disease as best response after treatment, and
no local progression occurred until the end of follow up
or time of death, this patient was counted as locally
controlled. Endoscopy findings or biopsy results were
included into response assessment if available, but rou-
tine biopsies after treatment were not performed. In
case of progression on imaging, endoscopy included
biopsy if possible were performed. Locoregional control
was defined as absence of tumor regrowth in the region
Table 1 Patients characteristics
Patients characteristics
gender
male 14 (82%)
female 3 (18%)
age (start of second RT course)
median 53
range 23-67
KI (start of second RT course)
90-100% 10 (59%)
70-80% 6 (35%)
60% 1 (6%)
primary T stage
Tx
a 2 (12%)
T1 1 (6%)
T2 3 (18%)
T3 4 (24%)
T4 2 (12%)
unknown 5 (29%)
primary N stage
N0 3 (18%)
N1 6 (35%)
N2 4 (24%)
N3 0 (0%)
unknown 4 (24%)
histology (WHO)
I 0 (0%)
II 3 (18%)
III 14 (82%)
recurrent T stage
rT1 3 (18%)
rT2 1 (6%)
rT3 1 (6%)
rT4 12 (71%)
recurrent N stage
rN0 15 (88%)
rN1
b 2 (12%)
a: 2 pts. were initially treated for cervical lymph nodes with cancer of
unknown primary, in both the nasopharyngeal region had been included into
the target volume,
b: one patient received neck dissection prior to
reirradiation, in one patient the neck recurrence was included into the target
volume of reirradiation, KI: Karnofsky index, age [years], staging according to
UICC TNM classification 6
th edition.
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Page 3 of 11of the treated recurrence and the bilateral cervical and
supraclavicular nodal areas based on best response after
treatment. In patients without further assessment of
local or locoregional control e.g. after development of
distant spread, the date of the last information about
the local status was used for calculation. Local control
(LC), Locoregional control (LRC), and Overall Survival
(OS) were calculated using the Kaplan-Meier method.
Differences in subgroups were tested for statistical sig-
nificance by the log rank test. Differences were consid-
ered statistically significant for a p-value of ≤ 0.05.
Results
The median follow up for the entire cohort was
20 months (6-84 months) and 31 months (10-84
months) in surviving patients.
Response to Reirradiation
Local response was documented by CT or MRI scans in all
patients. Complete response, defined as absence of mea-
surable tumor, was found in seven patients (41%) and four
patients showed partial response (24%) after treatment.
Another five patients showed stable disease on repeated
CT or MRI scans, whereas one patient had immediate
progressive disease after 2 months and was counted as
local recurrence. The group of patients with complete
response included all patients with rT stage 1-3, all
received reirradiation doses above 50 Gy, 5 of the 7
patients received concurrent chemotherapy and none of
them developed a local recurrence so far. In contrast, all
patients without complete response had rT4 stage, only
2 of them received irradiation doses above 50 Gy, concur-
rent systemic therapy had been administered in only 3 of
them, and all local recurrences were found in that group.
Local and Locoregional Control
Five patients developed measurable isolated local recur-
rences after reirradiation, resulting in estimated 1- and
2-year local control rates for the entire cohort of 76%
and 69%, respectively (see figure 2). Additional three
patients suffered from isolated nodal recurrences in the
neck region outside the reirradiation areas, resulting in
combined 1- and 2-year locoregional control rates of
59% and 52%, respectively.
In univariate analysis, local control was significantly
improved if complete response was achieved after reirra-
diation (p = 0.025, see figure 3). In fact, none of the
patients with complete response has developed a local
recurrence so far. A reirradiation dose of more than
50 Gy had also a significant impact on local control (p =
0.039, see figure 4). Trends to improved local control
were seen for lower rT stage (rT1-3 vs. rT4, p = 0.09, see
figure 5) and for concurrent systemic treatment (p =
0.16, see figure 6). Importantly, none of the patients with
rT stage 1-3 developed a local recurrence so far.
Overall survival and distant metastases
A total of 10 deaths have been observed, all related to dis-
ease progression. The median estimated overall survival
for the entire cohort was 23 months, transferring into 1-,
2- and 3-y-overall survival rates of 82%, 44% and 37%
(figure 7). As for local control, the achievement of com-
plete response was a strong prognostic factor for enhanced
overall survival (p < 0.001, see figure 8). Only one patient
of this group has died so far. Administration of concurrent
systemic therapy also had a strong impact on overall survi-
val (p < 0.001, see figure 9), with 6 of 8 patients in this
group still alive. A low rT stage (p = 0.032, see figure 10)
and a reirradiation dose above 50 Gy (p = 0.034, see figure
11) also significantly improved overall survival in univari-
ate analyses. A total of six patients developed distant
metastases during the follow-up period, three of them
without locoregional recurrence. In one patient, distant
metastases were confined to the lung, three patients suf-
fered from liver metastases and in two patients multiple
sites were involved at diagnosis of distant spread.
Figure 1 Example for dose distribution in axial, sagittal and frontal view. dotted line: 95% isodose.
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Reirradiation was generally well tolerated with no or
only minor acute toxicities mainly in patients with con-
current systemic treatment. Most patients developed a
minor mucositis, a grade III mucositis was found only
in two patients, with one of them suffering from a pre-
existing perforation of the palate due to tumor infiltra-
tion prior to reirradiation. Mild radiation erythema
(grade I) was found in 7 patients and one patient suf-
fered from localized patchy moist skin desquamation
(grade II). Three patients showed grade I/II leukopenia
or thrombocytopenia, all had received concurrent che-
motherapy. Nausea grade I/II was present in five
Table 2 Treatment characteristics
Treatment characteristics
primary RT course technique
2d 12 (71%)
3d 5 (29%)
primary RT dose (boost)
median 66
range 50-72
primary RT dose (nodal regions)
median 56
range 50-60
second RT course technique
IMRT 14 (82%)
FSRT 3 (18%)
second RT course dose
median 50,4
range 36-60
second RT PTV volume
median 127
range 26-347
time between RT courses
median 52
range 6-132
cumulative dose both RT courses
median 112
range 91-132
second RT course systemic therapy
concurrent chemotherapy 7 (41%)
concurrent immunotherapy 1 (6%)
adjuvant chemotherapy 2 (12%)
no chemotherapy 9 (53%)
all doses in Gy, IMRT: intensity modulated radiotherapy, FSRT: fractionated
stereotactic radiotherapy, PTV volume in ccm, time between RT courses in
months, chemotherapy platin-based in all patients, immunotherapy:
cetuximab.
Table 3 Maximum doses to critical organs at risk (OAR)
during reirradiation for the entire cohort
Dose to OAR median min max
brainstem 30 10 49
spinal cord 22 0 23
right optic nerv 25 1 43
left optic nerv 20 1 43
chiasma 11 1 39
all doses in Gy.
Time [months]
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Figure 2 Local control of the entire cohort.
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Figure 3 Local control according to reirradiation response.
Complete Response vs. No Complete Response, p = 0.025.
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Page 5 of 11patients, mainly attributed to chemotherapy also. One
patients developed mild brain edema, which resolved
after steroid medication. One patient suffered from a
localized parodontal abcess formation and one from
thrombosis of the axillary vein.
Late radiation toxicities from the first course of radia-
tion treatment were relatively common and occurred in
65% of the patients, mainly as xerostomia or sensory
alterations of taste, smell or hearing function. Late
radiation toxicity attributable to the second course of
radiation or worsening of pre-existing late toxicities
were observed in the majority of patients but most of
them were mild. Severe late radiation toxicities (grade
III) attributable to reirradiation were found in 5 patients
(29%). For detailed characteristics of late radiation toxi-
city see table 4.
Discussion
In the last decades combined chemoradiation has
emerged as the standard of care in patients suffering
Time [months]
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1,0
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> 50 Gy
Figure 4 Local control according to reirradiation dose.T o t a l
dose < 50 Gy vs. > 50 Gy, p = 0.039.
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Figure 5 Local control according to rT stage.r Ts t a g e1 - 3v s .r T
stage 4, p = 0.09.
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Figure 6 Local control according to concurrent systemic
therapy. Concurrent systemic therapy vs. no radiotherapy alone,
p = 0.16.
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Figure 7 Overall Survival of the entire cohort.
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Page 6 of 11from primary advanced nasopharyngeal cancer [1-6].
Local control and overall survival have further improved
through the introduction of modern radiotherapy tech-
niques which allowed dose escalation up to and beyond
70 Gy in conventional fractionation with an improved
toxicity profile [24-28]. However, isolated local recur-
rence still remains an issue in about 10% of the patients
and appears even more challenging to treat than in the
past because of the intensified prior treatment in many
patients. Currently available treatment options for recur-
rent nasopharyngeal cancer include surgery [29], che-
motherapy [30] and various techniques of reirradiation
like radiosurgery, fractionated stereotactic radiotherapy
(FSRT), brachytherapy using mould or gold grain tech-
niques and fractionated external beam radiotherapy
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Figure 8 Overall Survival according to reirradiation response.
Complete Response vs. No Complete Response, p < 0.001.
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Figure 9 Overall Survival according to concurrent systemic
therapy. Concurrent systemic therapy vs. no radiotherapy alone,
p < 0.001.
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Figure 10 Overall survival according to rT stage. rT stage 1-3 vs.
rT stage 4, p = 0.032.
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Figure 11 Overall survival according to reirradiation dose. Total
dose < 50 Gy vs. > 50 Gy, p = 0.034.
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Page 7 of 11[10-12,31]. Most of these options, namely surgery, radio-
surgery and brachytherapy techniques yield excellent
results in highly specialized, experienced centers, but are
usually restricted to small volume recurrences confined
to the nasopharynx and adjacent soft tissues [32]. In
contrast, systemic treatment alone hardly results in long
term survivors, and therefore it is usually restricted to
patients with metastatic disease as a palliative treatment
option [9,30]. For the remaining patient group, suffering
from isolated but locally advanced recurrent lesions,
external beam irradiation has been investigated using
2D or 3D treatment techniques, although this approach
seems to be difficult due to the large numbers of impor-
tant structures situated in the vicinity of a region that
was already irradiated to a high dose during the primary
treatment [32]. However, substantial local control rates
have been reported by several groups, especially using
modern 3D-RT techniques, but were commonly accom-
panied by high incidences of severe late toxicity [13-15].
For example, Zheng et al. [15] reported a 5-year-local
control rate of 71% after treating recurrent nasopharyn-
geal cancer with 3D-RT up to 70 Gy, but grade 3 toxici-
tiy was found in all patients with half of them suffering
from grade 4/5 side effects.
Intensity-modulated radiotherapy has been shown to
yield superior dose distribution and sparing of organs at
risk compared to 3D-conformal radiotherapy in many
sites of the body. In the nasopharyngeal region, Hsiung
et al. [16] also could show superior target coverage with
less dose to organs at risk, especially brainstem and
eyes, comparing IMRT with 5-field 3D-conformal RT
used for boost or salvage irradiation. Excellent local
control and overall survival rates beyond 90% have been
reported by several groups using IMRT in the treatment
of primary nasopharyngeal cancer with acceptable toxi-
city [24-28]. In our study, with the majority of patients
suffering from locally advanced recurrences treated with
moderate dose IMRT (median 50.4 Gy), we found a
complete response rate of 41%, with 1-and 2-year local
control rates of 76% and 69%, respectively. The corre-
sponding overall survival rates decreased from 82% after
one year to 44% after two years, probably due to the
relatively high rate of distant metastases occurring dur-
ing the follow-up period. It is possible that this patient
group belongs to a subset of patients with primarily
unfavourable biological tumor properties including the
tendency for early metastasis. The incidence of severe
late complications was 29%, which is lower than in most
of the studies using 2D- or 3D-conformal radiotherapy
[13-15], especially in terms of neurological side effects
like temporal lobe necrosis, brain stem damage or cra-
nial neuropathy. But despite the theoretically advantages
of IMRT, only few clinical reports exist about the use of
IMRT for recurrent nasopharyngeal cancer in the litera-
ture. For example Lu et al. [33] reported about 49
patients treated with high dose IMRT (68-70 Gy) which
resulted in a 100% local control rate after a median fol-
low up of 9 months. However, the incidence of late toxi-
cities was not reported probably due to the very short
follow-up time, excluding definite conclusions about the
influence of late toxicity on the overall outcome. Chua
et al. [7] reported on 31 cases treated with moderate
dose IMRT (median dose 54 Gy) with very similar
patient characteristics compared to our cohort consider-
ing age, gender, rT stage, time interval between the
radiation courses and primary treatment. They found
similar results, with a complete response rate of 58%,
1-year rates of locoregional control and survival of 56%
and 63% respectively and a severe late toxicity rate of
19%, suggesting good short-term control with acceptable
incidence of late side effects for this treatment concept.
In a recent update, their initial results transferred into a
5-year local control rate of 27%-43% depending on rT
stage, indicating reasonable long-term control and survi-
val in a substantial proportion of patients in this unfa-
vourable group with an acceptable toxicity profile [32].
Several prognostic factors have been discussed for out-
come after reirradiation treatment of locally recurrent
nasopharyngeal cancer, including age, performance
score, histology, rT stage, tumor volume, time interval
between radiotherapy courses, prior local failures, reirra-
diation dose and even EGFR-status [7,9,15,34-39]. As
our study included only a small number of patients,
conclusions considering prognostic factors should be
drawn with caution, given the known limitations of uni-
variate analyses in small cohorts. For example, it cannot
be ruled out that differences in outcome according to
treatment factors, for example radiation dose or simulta-
neous application of systemic therapy were biased by a
tendency to intensified treatment in less advanced
lesions. However, despite the small number of patients
in our study we found an impact of rT stage, tumor
response, reirradiation dose > 50 Gy and simultaneous
use of chemotherapy for local control and/or overall
Table 4 Severe late toxicities attributable to reirradiation
Late toxicity (grade III) n
alteration of taste
a 1
alteration of smell
a 1
hearing loss
a 2
cranial neuropathy 1
trismus 1
xerostomia
a 1
a: late radiation toxicities in these categories which occured after the first
course of radiation treatment and have not worsened after the second course
were excluded, some patients developed more than one late toxicitiy.
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age, gender and performance score showed no prognos-
tic value in our analysis.
The most consistent prognostic factor being reported
is rT stage [7,9,15,35,36]. Especially patients with inva-
sion of intracranial structures (rT4) had a particularly
poor local control and overall survival in most of the
series. In our cohort, all local recurrences were seen in
patients with rT4 stage resulting in 1- and 2-year local
control rates of only 67% and 56% and a 2-year overall
survival of only 28%. Chua et al [7] reported an even
more distinguished difference in their cohort with a 1-y-
locoregional control rate of only 35% in patients with
rT4 stage compared to 100% in rT1-3 stage patients,
but in contrast to our study, rT stage had no prognostic
value for overall survival in their series. The poor out-
come of patients with rT4 stage with respect to local
control and overall survival is possibly related to differ-
ent factors. The decreased local control may be caused
by suboptimal target coverage due to the constraints of
the nearby critical structures and the tendency to lower
overall dose prescription in heavily pre-treated patients
with advanced lesions in the fear of excess toxicity.
However, although the difference in overall survival
could obviously be at least partly attributed to uncon-
trolled local disease, these patients could also have a
higher risk of regional and distant failure per se. In our
study only one out of five patients with rT1-3 stage, but
5 out of 12 patients with rT4 stage developed distant
metastasis after reirradiation.
The second consistently reported prognostic factor is
reirradiation dose [9,15,35,38,39]. Several authors
described improvements in outcome for reirradiation
doses above 60 Gy [9,15,35], but in some of these series
high local control did not transfer into improved survi-
val and was rather accompanied by high rates of severe
complications probably responsible at least in part for
this difference. For example Zheng et al. [15] achieved
an excellent 5-year local control rate of 71% in a cohort
of less advanced lesions, whereas the 5-year overall sur-
vival rate was only 40%. Eleven of their 86 patients died
without signs of disease progression but showed severe
complications. In contrast, Chang et al. [39] observed
that a dose > 50 Gy already yielded better survival in
their series. In our cohort, doses above 50 Gy were asso-
ciated with improved local control and overall survival,
but this result could be influenced by a tendency to apply
higher doses in patients with less advanced rT stage.
However, for patients suffering from rT1-3 tumors, reir-
radiation doses of 50-60 Gy resulted in excellent short
term local control and overall survival in our and other
reported series [7], while in rT4 stage patients doses of
a b o u t5 0G ys e e mt oh a v eap a l l i a t i v ev a l u eo n l yi nm o s t
cases. However, whether further dose escalation in those
advanced patients will improve outcome remains uncer-
tain. According to our experience, sparing of adjacent
organs at risk can be difficult in rT4 patients even with
the use of IMRT and further dose escalation would prob-
ably distinctly increase late toxicity. One way to improve
outcome could be the use of newer radiotherapy techni-
ques like protons or heavy ions, which could allow a
superior dose distribution and sparing of normal tissues.
For example, Taheri-Kadhoda et al. [40] showed a super-
ior dose distribution in the nasopharyngeal area with
respect to target coverage and dose to organs at risk with
3-field intensity modulated proton therapy compared to
9-field step and shoot photon IMRT.
Another possible way to improve outcome could be
combined modality treatment using induction and/or con-
current systemic therapy. In our series, we found a trend
to improved local control and a significant improved over-
all survival in patients receiving concurrent systemic treat-
ment. Another series reported by Chua et al. [41] showed
a 1-year local control rate of 75% in advanced recurrences
after induction chemotherapy with cisplatin/gemcitabine
followed by reirradiation with IMRT. While induction
chemotherapy could not only allow better target coverage
and sparing of adjacent organs at risk through tumor
shrinkage, it may also be used to delay the second course
of RT in patients who relapse shortly after primary treat-
ment [32]. Concurrent chemotherapy has been shown to
improve response, local control and overall survival com-
pared to radiotherapy alone in the treatment of primary
nasopharyngeal cancer in many series and is now accepted
as the standard of care for advanced primary lesions [1-6].
In recurrent nasopharyngeal cancer it could also improve
the rate of complete responses, which had a significant
impact on local control and overall survival in our series.
Patients with complete response showed a 2-year local
control rate of 100% and a 2-year OS rate of 86% com-
pared to 45% and 12% in the group with residual disease.
Therefore combined modality approaches including
induction and/or concurrent systemic treatment could not
only be used to further improve outcome especially in
advanced (rT4) recurrent lesions but also for patient selec-
tion processes.
In conclusion, reirradiation using IMRT for local recur-
rences of nasopharyngeal cancer with moderate doses
yields excellent results in terms of local control and overall
survival in rT1-3 lesions. Acute and late toxicity seems to
be reduced compared to the results published with 2D- or
3D conformal treatment approaches. However, outcome
in locally advanced recurrent lesions (rT4) is still limited
and treatment with doses in the range of 50 Gy has to be
considered palliative in the majority of cases. Therefore
close monitoring of patients after primary treatment of
nasopharyngeal cancer should be mandatory in order to
detect local recurrences early enough to offer salvage
Roeder et al. Radiation Oncology 2011, 6:22
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Page 9 of 11options with curative intent. Combined modality
approaches or newer radiation technologies like protons
or heavy ions should be further investigated especially
considering advanced recurrent lesions.
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